Deferiprone (DFP)去鐵酮(鐵螯合劑)
產(chǎn)品編號 | 產(chǎn)品名稱 | 包裝規(guī)格 | 價格 |
NBS5883-100mg | Deferiprone (DFP)去鐵酮(鐵螯合劑) | 100mg | 123 |
NBS5883-1g | Deferiprone (DFP)去鐵酮(鐵螯合劑) | 1g | 291 |
NBS5883-5g | Deferiprone (DFP)去鐵酮(鐵螯合劑) | 5g | 729 |
產(chǎn)品簡介:
去鐵酮(Deferiprone, DFP)是一種鐵螯合劑,按照3:1比例(配基:鐵離子)與鐵結(jié)合,具抗氧化劑和神經(jīng)保護(hù)作用。DFP(100 μM)逆轉(zhuǎn)HT-1080纖維肉瘤細(xì)胞內(nèi)愛拉斯汀誘導(dǎo)的鐵死亡,另外,DFP能降低原代大鼠肝細(xì)胞的胞內(nèi)鐵水平以及脂質(zhì)過氧化,作用濃度分別是200 μM和50 μM。DFP(50mg/kg)能夠減低兔海馬內(nèi)膽固醇飲食誘導(dǎo)的Aβ42和Aβ40增加,以及tau和GSK-3β磷酸化。
產(chǎn)品特性:
1) 化學(xué)名:3-hydroxy-1,2-dimethyl-4(1H)-pyridinone
2) 同義名:CGP 37391、DN 18001AF
3) CAS NO:30652-11-0
4) 分子式:C7H9NO2
5) 分子量:139.15
6) 外觀:白色至類白色固體
7) 純度:≥98%
8) 溶解性:溶于甲醇(5mg/ml)、H2O(≥3mg/ml,需要超聲或加熱助溶)
保存條件:
-20℃避光干燥保存,至少2年有效。
本產(chǎn)品僅用于生命科學(xué)研究,不得用于醫(yī)學(xué)診斷及其他用途!
儲存液制備:
質(zhì)量 溶劑體積 濃度 | 1mg | 5mg | 10mg |
1mM | 7.1865 mL | 35.9324 mL | 71.8649 mL |
5mM | 1.4373 mL | 7.1865 mL | 14.3730 mL |
10mM | 0.7186 mL | 3.5932 mL | 7.1865 mL |
【溫馨提示】:請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。儲備液置于-80°C保存,約6個月有效;-20°C保存,約1個月有效。溶液儲存的過程中避免強光直射。
產(chǎn)品使用: 【源自文獻(xiàn),僅作參考】
文獻(xiàn)1,Liu, R.-Z.; Zhang, S.; Zhang, W.; Zhao, X.-Y.; Du, G.-H. Baicalein Attenuates Brain Iron Accumulation through Protecting Aconitase 1 from Oxidative Stress in Rotenone-Induced Parkinson’s Disease in Rats. Antioxidants 2023, 12, 12. https://doi.org/10.3390/antiox12010012
體內(nèi)研究(動物模型):
動物模型(Animal Model):Male SD rats
實驗方法(Assay):The rats were randomly divided into 5 groups: the control group, model group, BAI-300 group, BAI-150 group, and DFP-150 group. All of the groups received an intraperitoneal injection of 2.5 mg/kg rotenone q.d. for 6 weeks, except for the control group, which received an equal volume of vehicle. From the third week to the sixth week, the rats were administered 300 mg/kg of baicalein (BAI-300 group), 150 mg/kg baicalein (BAI-150 group), or 150 mg/kg of deferiprone (DFP-150 group) q.d. by gavage, while the control group and the model group received an equal volume of vehicle. The dose of baicalein was determined based on a previous study;the dose of deferiprone was based on its clinical trial (30 mg/kg/d) and preclinical studies.
文獻(xiàn)2,Fiorillo, M.; Tóth, F.; Brindisi, M.; Sotgia, F.; Lisanti, M.P. Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production. Cells 2020, 9, 1529. https://doi.org/10.3390/cells9061529
體外研究(細(xì)胞水平):
細(xì)胞類型(Cell Type):MCF7 cells
實驗方法(Assay):To evaluate the mitochondrial superoxide production, a MitoSOX probe was used.The MCF7 cells were treated with DFP (1 μM to 1000 μM) for 24 to 120 h. The vehicle alone (DMSO) control cells were processed in parallel.After 48 h, the cells were washed with PBS and incubated with MitoSOX (diluted in PBS/CM to a final concentration of 5 μM) for 10 min at 37 °C
注意事項:
1. 針對溶解性比較差的化合物,可通過37℃孵育以及超聲的方式來促進(jìn)其溶解。
2. 本品并非商業(yè)化的臨床藥物,僅用作科研用途,不得用作臨床診斷或治療,不得用于食品或藥品,絕對禁止用在人身上。
3. 為了您的安全和健康,請穿實驗服并戴一次性手套操作。
相關(guān)產(chǎn)品:
產(chǎn)品編號 | 產(chǎn)品名稱 | 包裝規(guī)格 |
5g | ||
1mg | ||
10mg | ||
1mg | ||
2mg | ||
1g | ||
25mg | ||
1g | ||
50ug | ||
24ug | ||
50nmol |